 So John, we're watching a host of different IPOs in the coming weeks. What are the main takeaways in your view? Well, next week's going to be a really big week for the IPO calendar. We've got a lot of companies coming public from a lot of different areas. There is a cloud-based tech company, Tintry, that's going to be coming out. I think that's going to be a hot one. There's a handful of biotech companies coming out, biotech companies with products for breast cancer, for heart disease, and other indications. And you're always looking to see what kind of partners these biotech companies have, because a lot of them don't have revenue yet. But the big one next week is going to be Blue Apron, 30 million shares out of Goldman Sachs. A lot of focus on the food industry with Amazon buying whole foods. I think it's going to be a hit on the early days in the market, but I think it's going to come out at a bit of a high valuation. So you might see it plateau in the few weeks after the initial public offer. And the Blue Apron CEO is also going to have reports that are suggesting quite a bit of voting power. Not exactly as much as SNAP CEO Evan Spiegel, but is that the new normal in some of these IPOs? I think the owners want the capital from the markets, but then they still want to keep control. So we're kind of seeing that play out. SNAP pulled it off. We'll see if Blue Apron is going to be as successful. Alright, John Eade, President of Argus Research, thanks so much. Thanks, Scott.